Gastric Bypass Surgery Reduces De Novo Cases of Type 2 Diabetes to Population Levels: A Nationwide Cohort Study From Sweden.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
14
8
2018
medline:
9
1
2020
entrez:
14
8
2018
Statut:
ppublish
Résumé
The aim of this study was to determine long-term changes in pharmacological treatment of type 2 diabetes after primary Roux-en-Y gastric bypass (RYGB) surgery, in patients with and without pharmacological treatment of diabetes preoperatively. Several studies have shown that gastric bypass has good effect on diabetes, at least in the short-term. This study is a nationwide cohort study using Swedish registers, with basically no patients lost to follow-up during up to 7 years after surgery. The effect of RYGB on type 2 diabetes drug treatment was evaluated in this nationwide matched cohort study. Participants were 22,047 adults with BMI ≥30 identified in the nationwide Scandinavian Surgical Obesity Registry, who underwent primary RYGB between 2007 and 2012. For each individual, up to 10 general population comparators were matched on birth year, sex, and place of residence. Prescription data were retrieved from the nationwide Swedish Prescribed Drug Register through September 2015. Incident use of pharmacological treatment was analyzed using Cox regression. Sixty-seven percent of patients with pharmacological treatment of type 2 diabetes before surgery were not using diabetes drugs 2 years after surgery and 61% of patients were not pharmacologically treated up to 7 years after surgery. In patients not using diabetes drugs at baseline, there were 189 new cases of pharmacological treatment of type 2 diabetes in the surgery group and 2319 in the matched general population comparators during a median follow-up of 4.6 years (incidence: 21.4 vs 27.9 per 10,000 person-years; adjusted hazard ratio 0.77, 95% confidence interval 0.67-0.89; P < 0.001). Gastric bypass surgery not only induces remission of pharmacological treatment of type 2 diabetes but also protects from new onset of pharmacological diabetes treatment. The effect seems to persist in most, but not all, patients over 7 years of follow-up.
Sections du résumé
OBJECTIVE
The aim of this study was to determine long-term changes in pharmacological treatment of type 2 diabetes after primary Roux-en-Y gastric bypass (RYGB) surgery, in patients with and without pharmacological treatment of diabetes preoperatively.
SUMMARY OF BACKGROUND DATA
Several studies have shown that gastric bypass has good effect on diabetes, at least in the short-term. This study is a nationwide cohort study using Swedish registers, with basically no patients lost to follow-up during up to 7 years after surgery.
METHODS
The effect of RYGB on type 2 diabetes drug treatment was evaluated in this nationwide matched cohort study. Participants were 22,047 adults with BMI ≥30 identified in the nationwide Scandinavian Surgical Obesity Registry, who underwent primary RYGB between 2007 and 2012. For each individual, up to 10 general population comparators were matched on birth year, sex, and place of residence. Prescription data were retrieved from the nationwide Swedish Prescribed Drug Register through September 2015. Incident use of pharmacological treatment was analyzed using Cox regression.
RESULTS
Sixty-seven percent of patients with pharmacological treatment of type 2 diabetes before surgery were not using diabetes drugs 2 years after surgery and 61% of patients were not pharmacologically treated up to 7 years after surgery. In patients not using diabetes drugs at baseline, there were 189 new cases of pharmacological treatment of type 2 diabetes in the surgery group and 2319 in the matched general population comparators during a median follow-up of 4.6 years (incidence: 21.4 vs 27.9 per 10,000 person-years; adjusted hazard ratio 0.77, 95% confidence interval 0.67-0.89; P < 0.001).
CONCLUSIONS
Gastric bypass surgery not only induces remission of pharmacological treatment of type 2 diabetes but also protects from new onset of pharmacological diabetes treatment. The effect seems to persist in most, but not all, patients over 7 years of follow-up.
Identifiants
pubmed: 30102631
doi: 10.1097/SLA.0000000000002983
pmc: PMC7306254
mid: NIHMS1594048
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
895-902Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK105948
Pays : United States
Références
JAMA. 2014 Jun 11;311(22):2297-304
pubmed: 24915261
Diabetes Care. 2017 Jan;40(Suppl 1):S11-S24
pubmed: 27979889
N Engl J Med. 2014 May 22;370(21):2002-13
pubmed: 24679060
JAMA. 2012 Sep 19;308(11):1122-31
pubmed: 22990271
Lancet Diabetes Endocrinol. 2015 Nov;3(11):855-65
pubmed: 26386667
J Intern Med. 2013 Mar;273(3):219-34
pubmed: 23163728
Lancet. 2015 Sep 5;386(9997):964-73
pubmed: 26369473
Diabetes Care. 2016 Jan;39(1):166-74
pubmed: 26628418
JAMA Surg. 2015 Oct;150(10):931-40
pubmed: 26132586
JAMA. 2014 Sep 3;312(9):934-42
pubmed: 25182102
Obes Surg. 2018 Aug;28(8):2247-2251
pubmed: 29524184
BMJ. 2013 Oct 22;347:f5934
pubmed: 24149519
JAMA. 2016 Jun 7;315(21):2284-91
pubmed: 27272580
JAMA. 2012 Sep 19;308(11):1132-41
pubmed: 22990272
Obes Surg. 2016 Aug;26(8):1814-20
pubmed: 26718983
Lancet. 2016 Apr 2;387(10026):1377-1396
pubmed: 27115820
Lancet Diabetes Endocrinol. 2017 Apr;5(4):271-279
pubmed: 28237791
JAMA. 2013 Dec 11;310(22):2416-25
pubmed: 24189773
N Engl J Med. 2004 Dec 23;351(26):2683-93
pubmed: 15616203
Lancet Diabetes Endocrinol. 2014 Dec;2(12):963-8
pubmed: 25466723
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
N Engl J Med. 2012 Aug 23;367(8):695-704
pubmed: 22913680
Diabetologia. 2016 May;59(5):945-53
pubmed: 26983924
Obes Surg. 2015 Oct;25(10):1893-900
pubmed: 25703826
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609